Cartesian Therapeutics, Inc. (RNAC) Stock Analysis

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a late clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for severe, refractory autoimmune diseases. Formed via a reverse merger between Selecta Biosciences and Cartesian Therapeutics on November 13, 2023, the pre-revenue company is headquartered in Frederick, Maryland. **Its core asset, Descartes-08, is a first-in-class autologous mRNA CAR-T therapy targeting BCMA, currently in the Phase 3 AURORA trial for generalized myasthenia gravis (gMG), with additional trials in myositis and juvenile dermatomyositis.** Descartes-08 delivers therapeutic efficacy without the severe toxicities of DNA-integrating viral vectors or preconditioning chemotherapy, enabling administration in a low-cost outpatient setting with zero observed cases of CRS or ICANS. The company recently secured up to USD 150 million in non-dilutive debt financing from K2 HealthVentures, extending its cash runway into 2028 and ensuring full funding for its key clinical readouts. **With a highly differentiated outpatient platform, near-term BLA submission targeted for mid-2027, and an enterprise value discounting its multi-billion dollar market potential, Cartesian offers asymmetric upside potential for long-term investors.**